Who are Switch from tenofovir to abacavir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Twice-daily ABC+3TC, Tenofovir/Emtricitabine, Entecavir+Fuzheng Huayu+TCM Granule, Symtuza® (TAF/FTC/DRV/c), AZT, "Raltegravir" and "Zidovudine".

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/switch-from-tenofovir-to-abacavir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Switch from tenofovir to abacavir — Competitive Intelligence Brief

Switch from tenofovir to abacavir (Switch from tenofovir to abacavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NRTI. Area: Infectious Diseases.

phase 3 NRTI Reverse transcriptase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Switch from tenofovir to abacavir (Switch from tenofovir to abacavir) — Germans Trias i Pujol Hospital. Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that works by inhibiting the replication of HIV.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Switch from tenofovir to abacavir TARGET	Switch from tenofovir to abacavir	Germans Trias i Pujol Hospital	phase 3	NRTI	Reverse transcriptase
Twice-daily ABC+3TC	Twice-daily ABC+3TC	Medical Research Council	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Tenofovir/Emtricitabine	Tenofovir/Emtricitabine	Bristol-Myers Squibb	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
Entecavir+Fuzheng Huayu+TCM Granule	Entecavir+Fuzheng Huayu+TCM Granule	ShuGuang Hospital	marketed	Nucleoside reverse transcriptase inhibitor + Traditional Chinese Medicine herbal combination	HBV reverse transcriptase (entecavir component); multiple herbal constituents with unclear specific molecular targets
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4
AZT	AZT	Johns Hopkins Bloomberg School of Public Health	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
"Raltegravir" and "Zidovudine"	"Raltegravir" and "Zidovudine"	Universidad Peruana Cayetano Heredia	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitor)	HIV integrase (raltegravir); HIV reverse transcriptase (zidovudine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NRTI class)

Germans Trias i Pujol Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Switch from tenofovir to abacavir — Competitive Intelligence Brief. https://druglandscape.com/ci/switch-from-tenofovir-to-abacavir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab